Trial · NCT02647437
Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia
NCT02647437, Not applicable, Completed, University of Colorado, Denver
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia. Trials, record NCT02647437. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02647437
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia
- NCT number
- NCT02647437
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 18 participants, actual
- Lead sponsor
- University of Colorado, Denver
- Conditions
- Schizophrenia
- Interventions
- Levetiracetam, Placebo
- First posted
- 2016-01-06
- Last updated
- 2026-08-21
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Resting-state Neuronal Response | 2 weeks | Mean neuronal response (measured via functional magnetic resonance imaging, fMRI) in the hippocampus during rest. This was measured as fractional amplitude of low frequency fluctuations (fALFF), which is a metric derived from resting-state fMRI that represents the power of regional spontaneous, intrinsic brain activity. This was calculated as the ratio of the low-frequency band power (0.01-0.1 Hz) to the total power across the entire frequency range of the Blood Oxygen Level-Dependent (BOLD) signal. Values generally range from 0 to 1, with higher values indicating a larger fraction of low-frequency fluctuations. |
| Secondary | Neurocognitive Function | 2 weeks | Cognitive function as measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) cognitive test battery. The RBANS consists of 12 subtests; raw scores from the 12 subtests are converted into age-based standardized index scores (mean=100, standard deviation \[SD\]=15) across five cognitive domains (Immediate Memory, Visuospatial/Constructional, Language, Attention, and Delayed Memory). The five index scores are summed, then translated to a final total scale score (mean=100, SD=15) using the conversion table in the RBANS manual. RBANS total scores range from 40-160, with lower scores indicating worse cognitive function. Scores one SD below the mean of 100 are indicative of mild cognitive impairment or the lower end of normal cognitive function, scores two SDs below the mean suggest moderate cognitive impairment, and scores three SD below the mean suggest severe cognitive impairment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| UL1TR001082 | Colorado Clinical and Translational Sciences Institute | SOKOL, RONALD J. | UNIVERSITY OF COLORADO DENVER | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | 2013 to 2017 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02647437
GET https://conductscience.org/api/trials/v1/NCT02647437/registered